These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
241 related articles for article (PubMed ID: 20652362)
1. Determination of the methylation status of MGMT in different regions within glioblastoma multiforme. Hamilton MG; Roldán G; Magliocco A; McIntyre JB; Parney I; Easaw JC J Neurooncol; 2011 Apr; 102(2):255-60. PubMed ID: 20652362 [TBL] [Abstract][Full Text] [Related]
2. MGMT expression and promoter methylation status may depend on the site of surgical sample collection within glioblastoma: a possible pitfall in stratification of patients? Della Puppa A; Persano L; Masi G; Rampazzo E; Sinigaglia A; Pistollato F; Denaro L; Barzon L; Palù G; Basso G; Scienza R; d'Avella D J Neurooncol; 2012 Jan; 106(1):33-41. PubMed ID: 21725802 [TBL] [Abstract][Full Text] [Related]
3. MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma. Donson AM; Addo-Yobo SO; Handler MH; Gore L; Foreman NK Pediatr Blood Cancer; 2007 Apr; 48(4):403-7. PubMed ID: 16609952 [TBL] [Abstract][Full Text] [Related]
4. MGMT inactivation and clinical response in newly diagnosed GBM patients treated with Gliadel. Grossman R; Burger P; Soudry E; Tyler B; Chaichana KL; Weingart J; Olivi A; Gallia GL; Sidransky D; Quiñones-Hinojosa A; Ye X; Brem H J Clin Neurosci; 2015 Dec; 22(12):1938-42. PubMed ID: 26249244 [TBL] [Abstract][Full Text] [Related]
5. MGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastoma. Rivera AL; Pelloski CE; Gilbert MR; Colman H; De La Cruz C; Sulman EP; Bekele BN; Aldape KD Neuro Oncol; 2010 Feb; 12(2):116-21. PubMed ID: 20150378 [TBL] [Abstract][Full Text] [Related]
6. Evaluation of MGMT promoter methylation status and correlation with temozolomide response in orthotopic glioblastoma xenograft model. Kitange GJ; Carlson BL; Mladek AC; Decker PA; Schroeder MA; Wu W; Grogan PT; Giannini C; Ballman KV; Buckner JC; James CD; Sarkaria JN J Neurooncol; 2009 Mar; 92(1):23-31. PubMed ID: 19011762 [TBL] [Abstract][Full Text] [Related]
7. Correlation between O6-methylguanine-DNA methyltransferase and survival in elderly patients with glioblastoma treated with radiotherapy plus concomitant and adjuvant temozolomide. Minniti G; Salvati M; Arcella A; Buttarelli F; D'Elia A; Lanzetta G; Esposito V; Scarpino S; Maurizi Enrici R; Giangaspero F J Neurooncol; 2011 Apr; 102(2):311-6. PubMed ID: 20686820 [TBL] [Abstract][Full Text] [Related]
8. Clinical correlation of MGMT protein expression and promoter methylation in Chinese glioblastoma patients. Tang K; Jin Q; Yan W; Zhang W; You G; Liu Y; Jiang T Med Oncol; 2012 Jun; 29(2):1292-6. PubMed ID: 21394635 [TBL] [Abstract][Full Text] [Related]
9. IDH mutation and MGMT promoter methylation are associated with the pseudoprogression and improved prognosis of glioblastoma multiforme patients who have undergone concurrent and adjuvant temozolomide-based chemoradiotherapy. Li H; Li J; Cheng G; Zhang J; Li X Clin Neurol Neurosurg; 2016 Dec; 151():31-36. PubMed ID: 27764705 [TBL] [Abstract][Full Text] [Related]
10. The number of methylated CpG sites within the MGMT promoter region linearly correlates with outcome in glioblastoma receiving alkylating agents. Siller S; Lauseker M; Karschnia P; Niyazi M; Eigenbrod S; Giese A; Tonn JC Acta Neuropathol Commun; 2021 Mar; 9(1):35. PubMed ID: 33663593 [TBL] [Abstract][Full Text] [Related]
11. MGMT gene promoter methylation as a potent prognostic factor in glioblastoma treated with temozolomide-based chemoradiotherapy: a single-institution study. Kim YS; Kim SH; Cho J; Kim JW; Chang JH; Kim DS; Lee KS; Suh CO Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):661-7. PubMed ID: 22414280 [TBL] [Abstract][Full Text] [Related]
13. Weak MGMT gene promoter methylation confers a clinically significant survival benefit in patients with newly diagnosed glioblastoma: a retrospective cohort study. Pinson H; Hallaert G; Van der Meulen J; Dedeurwaerdere F; Vanhauwaert D; Van den Broecke C; Van Dorpe J; Van Roost D; Kalala JP; Boterberg T J Neurooncol; 2020 Jan; 146(1):55-62. PubMed ID: 31701343 [TBL] [Abstract][Full Text] [Related]
14. Assessment of MGMT methylation status using high-performance liquid chromatography in newly diagnosed glioblastoma. Hanihara M; Miyake K; Watanabe A; Yamada Y; Oishi N; Kawataki T; Inukai T; Kondo T; Kinouchi H Clin Epigenetics; 2020 Nov; 12(1):174. PubMed ID: 33203454 [TBL] [Abstract][Full Text] [Related]
15. Human TERT promoter mutation enables survival advantage from MGMT promoter methylation in IDH1 wild-type primary glioblastoma treated by standard chemoradiotherapy. Nguyen HN; Lie A; Li T; Chowdhury R; Liu F; Ozer B; Wei B; Green RM; Ellingson BM; Wang HJ; Elashoff R; Liau LM; Yong WH; Nghiemphu PL; Cloughesy T; Lai A Neuro Oncol; 2017 Mar; 19(3):394-404. PubMed ID: 27571882 [TBL] [Abstract][Full Text] [Related]
16. MGMT promoter gene methylation in pediatric glioblastoma: analysis using MS-MLPA. Lee JY; Park CK; Park SH; Wang KC; Cho BK; Kim SK Childs Nerv Syst; 2011 Nov; 27(11):1877-83. PubMed ID: 21789683 [TBL] [Abstract][Full Text] [Related]
17. MGMT promoter methylation and glioblastoma: a comparison of analytical methods and of tumor specimens. Lattanzio L; Borgognone M; Mocellini C; Giordano F; Favata E; Fasano G; Vivenza D; Monteverde M; Tonissi F; Ghiglia A; Fillini C; Bernucci C; Merlano M; Lo Nigro C Int J Biol Markers; 2015 May; 30(2):e208-16. PubMed ID: 25588856 [TBL] [Abstract][Full Text] [Related]
18. MGMT promoter methylation status as a prognostic factor for the outcome of gamma knife radiosurgery for recurrent glioblastoma. Kim BS; Kong DS; Seol HJ; Nam DH; Lee JI J Neurooncol; 2017 Jul; 133(3):615-622. PubMed ID: 28536992 [TBL] [Abstract][Full Text] [Related]
19. Hegi ME; Genbrugge E; Gorlia T; Stupp R; Gilbert MR; Chinot OL; Nabors LB; Jones G; Van Criekinge W; Straub J; Weller M Clin Cancer Res; 2019 Mar; 25(6):1809-1816. PubMed ID: 30514777 [TBL] [Abstract][Full Text] [Related]
20. Relationship between tumor enhancement, edema, IDH1 mutational status, MGMT promoter methylation, and survival in glioblastoma. Carrillo JA; Lai A; Nghiemphu PL; Kim HJ; Phillips HS; Kharbanda S; Moftakhar P; Lalaezari S; Yong W; Ellingson BM; Cloughesy TF; Pope WB AJNR Am J Neuroradiol; 2012 Aug; 33(7):1349-55. PubMed ID: 22322613 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]